Main menu

Rapid nephrogenomics for thrombotic microangiopathies


Abstract

Our work underscores the feasibility and impact of swift genomic analysis via nanopore sequencing with adaptive sampling for the management of thrombotic microangiopathies (TMAs), a rare genetic condition in which molecular diagnosis can guide therapeutics. We demonstrate that diagnoses can be achieved in less than three days with hybrid complement factor H/complement factor H receptor gene detection within the same assay. Hybrid genes cannot be detected by short-read sequencing. This is in line with our previous study, in which we exemplified the utility of short-read exome sequencing for TMA and large-scale screening, with a turnaround time of weeks. Our current work represents a significant advancement beyond this, describing 18 prospective TMA cases with a molecular diagnosis made in the short timeframe of three days.

Biography

Professor Laurent Mesnard is Head of the Intensive Care Nephrology Unit at Assistance Publique Hopitaux de Paris Tenon Hospital, Sorbonne University, Paris, and a national coordinator for the French National plan of sequencing (PFMG2025) for rare adult kidney diseases. He co-coordinates the National Thrombotic Microangiopathies network (CNR-MAT). Prof. Mesnard’s team, located in Paris, use short-read whole-exome/genome sequencing for the clinical diagnosis of adult chronic kidney disease. They also develop applications for long-read sequencing technologies to accelerate clinical diagnosis for rare kidney diseases at their ICU admission. Another project (Allogenomics) aims to develop new metrics to evaluate the risk of chronic kidney graft failure and better allocation strategies for kidney transplantation.

Authors: Prof. Laurent Mesnard

入门指南

购买 MinION 启动包 Nanopore 商城 测序服务提供商 全球代理商

纳米孔技术

订阅 Nanopore 更新 资源库及发表刊物 什么是 Nanopore 社区

关于 Oxford Nanopore

新闻 公司历程 可持续发展 领导团队 媒体资源和联系方式 投资者 合作者 在 Oxford Nanopore 工作 职位空缺 商业信息 BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Chinese flag